Patient-reported outcomes from KATHERINE: a phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal growth factor receptor 2-positive breast cancer
Nom du journal : Cancer
Année : 2020
Volume : 126
Page de départ : 3132
Page de fin : 3139